Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Sabrina Chiara Cecere"'
Autor:
Luigi Portella, Giulia Bertolini, Giuseppe Guardascione, Dario Guido Di Febbraro, Caterina Ieranò, Crescenzo D'Alterio, Giuseppina Rea, Maria Napolitano, Sara Santagata, Anna Maria Trotta, Rosa Camerlingo, Emilia Scarpa, Sabrina Chiara Cecere, Alessandro Ottaiano, Giuliano Palumbo, Alessandro Morabito, Teresa Somma, Giuseppe De Rosa, Laura Mayol, Roberto Pacelli, Sandro Pignata, Stefania Scala
Publikováno v:
Heliyon, Vol 10, Iss 15, Pp e35524- (2024)
Background: Circulating Tumor Cells (CTCs) represent a small, heterogeneous population that comprise the minority of cells able to develop metastasis. To trap and characterize CTCs with metastatic attitude, a CXCL12-loaded hyaluronic-gel (CLG) was de
Externí odkaz:
https://doaj.org/article/7a5251e405c146bc825e22f84743a27f
Autor:
Anna Passarelli, Carmela Pisano, Elisabetta Coppola, Jole Ventriglia, Sabrina Chiara Cecere, Marilena Di Napoli, Luciano Carideo, Secondo Lastoria, Sandro Pignata
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Cervical cancer (CC) is the second most commonly diagnosed cancer and the third leading cause of cancer death among females. The options of treatment for recurrent/advanced CC are limited and patients experiencing recurrence after first line platinum
Externí odkaz:
https://doaj.org/article/13637c934c6e47e7b047a0176efec119
Autor:
Luca Forlani, Loris De Cecco, Vittorio Simeon, Biagio Paolini, Marina Bagnoli, Sabrina Chiara Cecere, Anna Spina, Eleonora Citeroni, Eliana Bignotti, Domenica Lorusso, Laura Arenare, Daniela Russo, Carmine De Angelis, Laura Ardighieri, Giosuè Scognamiglio, Michele Del Sesto, Germana Tognon, Daniela Califano, Clorinda Schettino, Paolo Chiodini, Francesco Perrone, Delia Mezzanzanica, Sandro Pignata, Antonella Tomassetti
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-17 (2023)
Abstract Background Validated prognostic biomarkers for anti-angiogenic therapy using the anti-VEGF antibody Bevacizumab in ovarian cancer (OC) patients are still an unmet clinical need. The EGFR can contribute to cancer-associated biological mechani
Externí odkaz:
https://doaj.org/article/218fe5829cc64926a70c90f947c39308
Autor:
Umberto Malapelle, Stefano Uccella, Sabrina Chiara Cecere, Carmine De Angelis, Pierluigi Giampaolino
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/2f6f0f6da10a46089c75dd4f810e942c
Autor:
Anna Passarelli, Jole Ventriglia, Carmela Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Sabrina Rossetti, Rosa Tambaro, Luca Tarotto, Francesco Fiore, Alberto Farolfi, Michele Bartoletti, Sandro Pignata
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
Endometrial cancer (EC) is the most common gynecologic cancer in Europe and its prevalence is increasing. EC includes a biological and clinical heterogeneous group of tumors, usually classified as type I (endometrioid) or type II (non-endometrioid) b
Externí odkaz:
https://doaj.org/article/195e07dbdcf3463fa5306ed4d9466769
Autor:
Anna Passarelli, Carmela Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Sabrina Rossetti, Rosa Tambaro, Jole Ventriglia, Federica Gherardi, Eva Iannacone, Sergio Setola Venanzio, Francesco Fiore, Michele Bartoletti, Giosuè Scognamiglio, Daniela Califano, Sandro Pignata
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Immunotherapy is acquiring a primary role in treating endometrial cancer (EC) with a relevant benefit for many patients. Regardless, patients progressing during immunotherapy or those who are resistant represent an unmet need. The mechanisms of immun
Externí odkaz:
https://doaj.org/article/a566ec8355c14cb985e3d260165dc78e
Autor:
Roberto Buonaiuto, Giuseppe Neola, Sabrina Chiara Cecere, Aldo Caltavituro, Amedeo Cefaliello, Erica Pietroluongo, Pietro De Placido, Mario Giuliano, Grazia Arpino, Carmine De Angelis
Publikováno v:
Biomolecules, Vol 13, Iss 4, p 653 (2023)
Ovarian cancer (OC) is the leading cause of death from gynecological malignancies worldwide. Fortunately, recent advances in OC biology and the discovery of novel therapeutic targets have led to the development of novel therapeutic agents that may im
Externí odkaz:
https://doaj.org/article/b4755a5be30947c0853fe116d4f49cfd
Autor:
Eleni Karamouza, Rosalind M. Glasspool, Caroline Kelly, Liz-Anne Lewsley, Karen Carty, Gunnar B. Kristensen, Josee-Lyne Ethier, Tatsuo Kagimura, Nozomu Yanaihara, Sabrina Chiara Cecere, Benoit You, Ingrid A. Boere, Eric Pujade-Lauraine, Isabelle Ray-Coquard, Cécile Proust-Lima, Xavier Paoletti
Publikováno v:
Cancers, Vol 15, Iss 6, p 1823 (2023)
(1) Background: Cancer antigen 125 (CA-125) is a protein produced by ovarian cancer cells that is used for patients’ monitoring. However, the best ways to analyze its decline and prognostic role are poorly quantified. (2) Methods: We leveraged indi
Externí odkaz:
https://doaj.org/article/3d6ea15b1a234135a95e0b9e7a424411
Autor:
Eros Azzalini, Domenico Tierno, Michele Bartoletti, Renzo Barbazza, Giorgio Giorda, Fabio Puglisi, Sabrina Chiara Cecere, Nunzia Simona Losito, Daniela Russo, Giorgio Stanta, Vincenzo Canzonieri, Serena Bonin
Publikováno v:
Cancers, Vol 14, Iss 2, p 304 (2022)
High-grade serous ovarian cancer (HGSOC) is among the deadliest gynecological malignancies. The acquired resistance to platinum-based therapies and the intrinsic heterogeneity of the disease contribute to the low survival rate. To improve patients’
Externí odkaz:
https://doaj.org/article/c12a32d59c1f48478850297041802d52
Autor:
Daniela Califano, Daniela Gallo, Gian Luca Rampioni Vinciguerra, Rossella De Cecio, Laura Arenare, Simona Signoriello, Daniela Russo, Gabriella Ferrandina, Francesca Citron, Nunzia Simona Losito, Piera Gargiulo, Vittorio Simeon, Giovanni Scambia, Sabrina Chiara Cecere, Marco Montella, Nicoletta Colombo, Germana Tognon, Eliana Bignotti, Gian Franco Zannoni, Vincenzo Canzonieri, Alessandra Ciucci, Anna Spina, Giosuè Scognamiglio, Michele Del Sesto, Clorinda Schettino, Maria Carmela Piccirillo, Francesco Perrone, Paolo Chiodini, Sandro Pignata, Gustavo Baldassarre
Publikováno v:
Cancers, Vol 13, Iss 20, p 5152 (2021)
Background. Epithelial ovarian cancer (EOC) is a rare, highly lethal disease. In a subset of high grade EOC patients, maintenance therapy with the antiangiogenic drug Bevacizumab (BEV) is a valuable option. To date, no validated predictive or prognos
Externí odkaz:
https://doaj.org/article/a247cff30305469eafdd5d9e3c60bf05